Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Quantum-Si (QSI) has announced the granting of 44,893 restricted stock units (RSUs) to new employees through its 2023 Inducement Equity Incentive Plan. The grants, approved by the Compensation Committee of QSI's Board of Directors, serve as inducement material for new hires in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs will follow a vesting schedule where 25% will vest on March 20, 2026, with the remaining portion vesting in 12 equal quarterly installments thereafter. Vesting is contingent upon continued employment with the company. These equity awards are exclusively granted to individuals who were not previously QSI employees, as part of their employment compensation package.

Positive

• Company demonstrates ability to attract new talent with equity compensation

Negative

• Potential future dilution for existing shareholders from 44,893 new RSUs
• Long vesting period (4 years) may impact employee retention

BRANFORD, Conn.--(BUSINESS WIRE)-- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company^™, today announced that the Compensation Committee of Quantum-Si’s Board of Directors has granted 44,893 restricted stock units (“RSUs”) to new employees under the Company’s previously adopted Quantum-Si Incorporated 2023 Inducement Equity Incentive Plan, as amended (the “2023 Inducement Plan”). The RSUs were granted as an inducement material to the new employees becoming an employee of Quantum-Si in accordance with Nasdaq Listing Rule 5635(c)(4).

The 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Quantum-Si (or following a bona fide period of non-employment), as an inducement material to such individuals entering into employment with Quantum-Si, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The RSUs will vest 25% on March 20, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the employee’s continued employment with Quantum-Si on such vesting dates. The RSUs are subject to the terms and conditions of the 2023 Inducement Plan and an RSU agreement covering the grant.

About Quantum-Si Incorporated

Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s Platinum^® instruments enable Next-Gen Protein Sequencing™ that advances proteomic research, drug discovery, and diagnostics beyond what has been possible with existing proteomic tools. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instruments and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250117877983/en/

Investor Contact

Jeff Keyes

Chief Financial Officer

ir@quantum-si.com

Media Contact

Katherine Atkinson SVP

Commercial Marketing

media@quantum-si.com

Source: Quantum-Si Incorporated

FAQ

How many RSUs did Quantum-Si (QSI) grant to new employees in this announcement?

Quantum-Si granted 44,893 restricted stock units (RSUs) to new employees.

What is the vesting schedule for Quantum-Si's (QSI) newly granted RSUs?

The RSUs will vest 25% on March 20, 2026, with the remaining 75% vesting in 12 equal quarterly installments thereafter.

What is the purpose of Quantum-Si's (QSI) 2023 Inducement Plan?

The 2023 Inducement Plan is exclusively used for granting equity awards to new employees as an inducement for joining Quantum-Si, in accordance with Nasdaq Rule 5635(c)(4).

What conditions must be met for the QSI RSUs to vest?

The RSUs will vest only if the employee maintains continued employment with Quantum-Si through the vesting dates.